Can a pill shrink advanced tumors? a new drug steps into the spotlight

NCT ID NCT07749703

Ongoing Disease control Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Aug 06, 2026 · Last updated Aug 12, 2026 · Updated 3 times

Summary

This early-stage trial is testing an experimental pill called SIM0532 in adults with advanced solid tumors that have not responded to standard treatments. The study is split into two parts: first, to find a safe dose, and then to see if the drug can shrink tumors or slow their growth. Researchers will also measure how the drug moves through the body and how long any benefit lasts.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SIM0532 tablets
What this could lead to: If successful, this could lead to a new oral treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong: This is an early, first-in-human study, so the drug may not be safe or effective. Side effects are unknown, and the results may not lead to a widely available treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HISTOLOGICALLY OR CYTOLOGICALLY CONFIRMED ADVANCED SOLID TUMORS

Contacts and locations

Locations

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, China
Shandong Cancer Hospital and Institute

Jinan, Shandong, China
Shanghai Pulmonary Hospital

Shanghai, Shanghai Municipality, China
The First Affiliated Hospital of University of Science and Technology of China

Hefei, Anhui, China
The First Hospital of China Medical University

Shenyang, Liaoning, China
Zhejiang Cancer Hospital

Hangzhou, Zhejiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.